CONMED Reports Strong Q2 Earnings Amid Organic Growth
CONMED Corporation (NYSE:CNMD) reported better-than-expected second-quarter results for fiscal year 2026, with organic sales rising by 6% and adjusted earnings per share increasing to $1.38 from $1.15 a year ago. The company benefited from an unexpected tariff refund of $0.21 per share but still exceeded its guidance without it. Growth was driven primarily by general surgery products such as AirSeal and Buffalo Filter, along with international orthopedics including BioBrace. However, U.S. orthopedic sales were flat due to a reorganization in the commercial team. CONMED raised its full-year adjusted EPS outlook but narrowed organic sales growth guidance. The company also refinanced $645.2 million of convertible notes and repurchased them ahead of their 2027 maturity date, signaling confidence in its financial position.
Topics: adjusted earnings per share financial performance free cash flow organic sales growth tariff refunds